OTCMKTS:BLOZF

Cannabix Technologies Competitors

$1.04
-0.03 (-2.81 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.00
Now: $1.04
$1.07
50-Day Range
$1.04
MA: $1.19
$1.43
52-Week Range
$0.26
Now: $1.04
$1.96
Volume142,185 shs
Average Volume599,025 shs
Market Capitalization$109.10 million
P/E RatioN/A
Dividend YieldN/A
Beta2.94

Competitors

Cannabix Technologies (OTCMKTS:BLOZF) Vs. ASXC, ITMR, VMD, TLIS, XTNT, and GBS

Should you be buying BLOZF stock or one of its competitors? Companies in the industry of "medical devices" are considered alternatives and competitors to Cannabix Technologies, including Asensus Surgical (ASXC), Itamar Medical (ITMR), Viemed Healthcare (VMD), Talis Biomedical (TLIS), Xtant Medical (XTNT), and GBS (GBS).

Asensus Surgical (NYSE:ASXC) and Cannabix Technologies (OTCMKTS:BLOZF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

0.1% of Cannabix Technologies shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Asensus Surgical and Cannabix Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Asensus SurgicalN/AN/AN/AN/AN/A
Cannabix TechnologiesN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Asensus Surgical and Cannabix Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Asensus Surgical01002.00
Cannabix Technologies0000N/A

Profitability

This table compares Asensus Surgical and Cannabix Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Asensus SurgicalN/AN/AN/A
Cannabix TechnologiesN/AN/AN/A

Summary

Cannabix Technologies beats Asensus Surgical on 1 of the 1 factors compared between the two stocks.

Cannabix Technologies (OTCMKTS:BLOZF) and Itamar Medical (NASDAQ:ITMR) are both small-cap business services companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Analyst Ratings

This is a breakdown of current ratings for Cannabix Technologies and Itamar Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cannabix Technologies0000N/A
Itamar Medical00503.00

Itamar Medical has a consensus price target of $31.00, suggesting a potential upside of 30.97%. Given Itamar Medical's higher possible upside, analysts plainly believe Itamar Medical is more favorable than Cannabix Technologies.

Insider and Institutional Ownership

0.1% of Cannabix Technologies shares are held by institutional investors. Comparatively, 29.4% of Itamar Medical shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Cannabix Technologies has a beta of 2.94, suggesting that its share price is 194% more volatile than the S&P 500. Comparatively, Itamar Medical has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.

Profitability

This table compares Cannabix Technologies and Itamar Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cannabix TechnologiesN/AN/AN/A
Itamar MedicalN/AN/AN/A

Valuation & Earnings

This table compares Cannabix Technologies and Itamar Medical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cannabix TechnologiesN/AN/AN/AN/AN/A
Itamar Medical$31.26 million12.20$-6,443,200.00($0.40)-59.18

Cannabix Technologies has higher earnings, but lower revenue than Itamar Medical.

Summary

Itamar Medical beats Cannabix Technologies on 4 of the 5 factors compared between the two stocks.

Viemed Healthcare (NASDAQ:VMD) and Cannabix Technologies (OTCMKTS:BLOZF) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Viemed Healthcare and Cannabix Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viemed Healthcare01302.75
Cannabix Technologies0000N/A

Viemed Healthcare currently has a consensus target price of $12.50, suggesting a potential upside of 28.87%. Given Viemed Healthcare's higher probable upside, research analysts plainly believe Viemed Healthcare is more favorable than Cannabix Technologies.

Insider and Institutional Ownership

0.1% of Cannabix Technologies shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Viemed Healthcare and Cannabix Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viemed HealthcareN/AN/AN/AN/AN/A
Cannabix TechnologiesN/AN/AN/AN/AN/A

Profitability

This table compares Viemed Healthcare and Cannabix Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viemed HealthcareN/AN/AN/A
Cannabix TechnologiesN/AN/AN/A

Summary

Viemed Healthcare beats Cannabix Technologies on 2 of the 3 factors compared between the two stocks.

Talis Biomedical (NASDAQ:TLIS) and Cannabix Technologies (OTCMKTS:BLOZF) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Valuation & Earnings

This table compares Talis Biomedical and Cannabix Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Talis BiomedicalN/AN/AN/AN/AN/A
Cannabix TechnologiesN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for Talis Biomedical and Cannabix Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Talis Biomedical01302.75
Cannabix Technologies0000N/A

Talis Biomedical currently has a consensus target price of $16.75, suggesting a potential upside of 20.07%. Given Talis Biomedical's higher probable upside, equities analysts clearly believe Talis Biomedical is more favorable than Cannabix Technologies.

Profitability

This table compares Talis Biomedical and Cannabix Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Talis BiomedicalN/AN/AN/A
Cannabix TechnologiesN/AN/AN/A

Insider & Institutional Ownership

0.1% of Cannabix Technologies shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Talis Biomedical beats Cannabix Technologies on 2 of the 3 factors compared between the two stocks.

Cannabix Technologies (OTCMKTS:BLOZF) and Xtant Medical (NYSEAMERICAN:XTNT) are both small-cap business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Insider and Institutional Ownership

0.1% of Cannabix Technologies shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Cannabix Technologies and Xtant Medical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cannabix TechnologiesN/AN/AN/AN/AN/A
Xtant MedicalN/AN/AN/AN/AN/A

Profitability

This table compares Cannabix Technologies and Xtant Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cannabix TechnologiesN/AN/AN/A
Xtant MedicalN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Cannabix Technologies and Xtant Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cannabix Technologies0000N/A
Xtant Medical0000N/A

Summary

Cannabix Technologies beats Xtant Medical on 1 of the 1 factors compared between the two stocks.

GBS (NYSE:GBS) and Cannabix Technologies (OTCMKTS:BLOZF) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Insider and Institutional Ownership

0.1% of Cannabix Technologies shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares GBS and Cannabix Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GBSN/AN/AN/A
Cannabix TechnologiesN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for GBS and Cannabix Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GBS0000N/A
Cannabix Technologies0000N/A

Earnings and Valuation

This table compares GBS and Cannabix Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GBSN/AN/AN/AN/AN/A
Cannabix TechnologiesN/AN/AN/AN/AN/A

Summary

Cannabix Technologies beats GBS on 1 of the 1 factors compared between the two stocks.


Cannabix Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ASXC
Asensus Surgical
0.0$1.75-7.4%$407.03 millionN/A0.00Analyst Downgrade
Gap Up
Itamar Medical logo
ITMR
Itamar Medical
1.3$23.67-2.0%$381.28 million$31.26 million-35.33Gap Up
Viemed Healthcare logo
VMD
Viemed Healthcare
1.1$9.70-0.9%$380.09 millionN/A0.00
Talis Biomedical logo
TLIS
Talis Biomedical
1.6$13.95-4.4%$357.65 millionN/A0.00
Xtant Medical logo
XTNT
Xtant Medical
0.6$1.92-11.5%$166.48 millionN/A0.00Decrease in Short Interest
Gap Up
GBS logo
GBS
GBS
0.3$4.65-1.7%$55.22 millionN/A0.00News Coverage
Gap Up
MRIC
MRI Interventions
0.5N/AN/A$52.92 millionN/A0.00Gap Up
Cochlear logo
CHEOF
Cochlear
0.5$172.00-0.0%$0.00N/A0.00Increase in Short Interest
Cochlear logo
CHEOY
Cochlear
0.4$87.49-0.3%$0.00N/A0.00High Trading Volume
Electromedical Technologies logo
EMED
Electromedical Technologies
0.0$0.15-0.0%$0.00N/A0.00
GN Store Nord A/S logo
GGNDF
GN Store Nord A/S
0.5$84.20-0.0%$0.00N/A0.00News Coverage
Ion Beam Applications logo
IOBCF
Ion Beam Applications
0.4$21.50-0.0%$0.00N/A0.00Decrease in Short Interest
Medigus logo
MDGS
Medigus
1.7$1.69-1.2%$0.00N/A0.00Gap Up
NeuroOne Medical Technologies logo
NMTC
NeuroOne Medical Technologies
0.6N/AN/A$0.00N/A0.00
ELXMF
Nova Eye Medical
0.5$0.23-0.0%$0.00N/A0.00
Odyssey Group International logo
ODYY
Odyssey Group International
0.0$0.78-9.0%$0.00N/A0.00Increase in Short Interest
Ortho Regenerative Technologies logo
ORTIF
Ortho Regenerative Technologies
0.3$0.44-1.1%$0.00N/A0.00Gap Up
NWFFF
Perimeter Medical Imaging AI
1.0$3.33-0.3%$0.00N/A0.00High Trading Volume
News Coverage
PYNKF
Perimeter Medical Imaging AI
1.7$3.33-0.3%$0.00N/A0.00High Trading Volume
News Coverage
PetVivo logo
PETV
PetVivo
0.4$10.00-2.5%$0.00N/A0.00News Coverage
PTQQF
Protech Home Medical
1.7$1.70-1.2%$0.00N/A0.00Increase in Short Interest
Gap Down
VICA
Rafina Innovations
0.4$0.19-18.9%$0.00N/A0.00Gap Up
Vycor Medical logo
VYCO
Vycor Medical
0.5$0.17-0.0%$0.00N/A0.00
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.